490 related articles for article (PubMed ID: 15193263)
1. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Ma XJ; Wang Z; Ryan PD; Isakoff SJ; Barmettler A; Fuller A; Muir B; Mohapatra G; Salunga R; Tuggle JT; Tran Y; Tran D; Tassin A; Amon P; Wang W; Wang W; Enright E; Stecker K; Estepa-Sabal E; Smith B; Younger J; Balis U; Michaelson J; Bhan A; Habin K; Baer TM; Brugge J; Haber DA; Erlander MG; Sgroi DC
Cancer Cell; 2004 Jun; 5(6):607-16. PubMed ID: 15193263
[TBL] [Abstract][Full Text] [Related]
2. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
[TBL] [Abstract][Full Text] [Related]
3. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Habel LA; Sakoda LC; Achacoso N; Ma XJ; Erlander MG; Sgroi DC; Fehrenbacher L; Greenberg D; Quesenberry CP
Breast Cancer Res; 2013 Mar; 15(2):R24. PubMed ID: 23497539
[TBL] [Abstract][Full Text] [Related]
4. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
[TBL] [Abstract][Full Text] [Related]
6. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Goetz MP; Suman VJ; Ingle JN; Nibbe AM; Visscher DW; Reynolds CA; Lingle WL; Erlander M; Ma XJ; Sgroi DC; Perez EA; Couch FJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2080-7. PubMed ID: 16609019
[TBL] [Abstract][Full Text] [Related]
7. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
[TBL] [Abstract][Full Text] [Related]
8. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.
Jerevall PL; Jansson A; Fornander T; Skoog L; Nordenskjöld B; Stål O
Breast Cancer Res; 2010; 12(4):R53. PubMed ID: 20649975
[TBL] [Abstract][Full Text] [Related]
9. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer.
Rodriguez BA; Cheng AS; Yan PS; Potter D; Agosto-Perez FJ; Shapiro CL; Huang TH
Carcinogenesis; 2008 Jul; 29(7):1459-65. PubMed ID: 18499701
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
14. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
15. Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.
Zhao L; Zhu S; Gao Y; Wang Y
Tumour Biol; 2014 Apr; 35(4):3113-7. PubMed ID: 24264313
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
Jerevall PL; Ma XJ; Li H; Salunga R; Kesty NC; Erlander MG; Sgroi DC; Holmlund B; Skoog L; Fornander T; Nordenskjöld B; Stål O
Br J Cancer; 2011 May; 104(11):1762-9. PubMed ID: 21559019
[TBL] [Abstract][Full Text] [Related]
17. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
18. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.
Sevinc ED; Egeli U; Cecener G; Tezcan G; Tunca B; Gokgoz S; Tasdelen I; Tolunay S; Evrensel T
Asian Pac J Cancer Prev; 2015; 16(1):291-7. PubMed ID: 25640367
[TBL] [Abstract][Full Text] [Related]
19. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
[TBL] [Abstract][Full Text] [Related]
20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
